An Evaluation of the Risk Factors and Respiratory Function Test Change of Children with Cystic Fibrosis Who Contracted COVID-19 Infection

Basit Öğe Kaydı
dc.authoridözaslan, mehmet mustafa/0000-0003-0611-0852
dc.authorwosidözaslan, mehmet mustafa/HPH-8987-2023
dc.contributor.authorOezaslan, Mehmet Mustafa
dc.contributor.authorSenol, Handan Duman
dc.contributor.authorBarlik, Meral
dc.contributor.authorcoksuer, Fevziye
dc.contributor.authorDindar, Bahar Girgin
dc.contributor.authorDemir, Esen
dc.contributor.authorGuelen, Figen
dc.date.accessioned2024-08-25T18:45:27Z
dc.date.available2024-08-25T18:45:27Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), was declared a global pandemic in March 2020, with millions of infected cases worldwide. Although the course is usually mild in the pediatric age group, there are unknown factors in patients with chronic lung diseases. The aim of this study was to determine the demographic characteristics and the clinical course of patients with cystic fibrosis who contracted COVID-19 infection. Methods A total of 128 patients with cystic fibrosis who were under follow-up in our clinic were separated into two groups: those who had been infected with COVID-19 and those who had not. The COVID-19-positive patients were then grouped as those who were hospitalized and those treated as outpatients. In the COVID-19 group, the spirometry values of the patients before the infection were compared with those measured at 3 and 6 months after the infection. Results The COVID-19 group comprised 34 (25.6%) cystic fibrosis patients with a mean age of 108.2 +/- 60.8 months who contracted COVID- 19 between April 2020 and October 2022. The rates of chronic bacterial colonization and allergic bronchopulmonary aspergillosis were significantly higher in the COVID-19 group (p = 0.001 and 0.005). Eight of the 34 patients were hospitalized, and 26 were isolated at home. Five patients required oxygen, and the forced expiratory volume in 1 second (FEV1) and forced vital capacity ( FVC) values were lower. Conclusion A severe course of COVID-19 was not seen in any of the cystic fibrosis patients. A greater number of patients with chronic respiratory tract bacterial colonization and allergic bronchopulmonary aspergillosis were hospitalized.en_US
dc.description.sponsorshipEge University Office of Scientific Research Projects [22-7T/32]en_US
dc.description.sponsorshipThe study was approved by Ege University Clinical Research Ethics Committee and financially supported by Ege University Office of Scientific Research Projects.(Project No: 22-7T/32).en_US
dc.identifier.doi10.1055/s-0043-1769902
dc.identifier.issn1305-7707
dc.identifier.issn1305-7693
dc.identifier.urihttps://doi.org/10.1055/s-0043-1769902
dc.identifier.urihttps://hdl.handle.net/11454/101571
dc.identifier.wosWOS:001006991700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherGeorg Thieme Verlag Kgen_US
dc.relation.ispartofJournal of Pediatric Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectcystic fibrosisen_US
dc.subjectCOVID-19en_US
dc.subjectchildrenen_US
dc.titleAn Evaluation of the Risk Factors and Respiratory Function Test Change of Children with Cystic Fibrosis Who Contracted COVID-19 Infectionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu